Every company speaks of its dedication to ethics & compliance. Amicus is of course no exception – we are deeply committed to performance with integrity. Important sources of our strong commitment are the tone and direction from our CEO and Board, as well as the unusually strong bond and friendship between members of the Amicus leadership and executive teams which permeate the culture of our organization.
As colleagues, we respect and trust each other. As friends, we go the extra mile to support each other in our mutual corporate objectives. And this cuts across all departments. It is that support, and understanding that compliance is a shared responsibility, that makes Amicus so special and its commitment to ethics & compliance so meaningful.
Patrik Florencio
Chief Compliance & Risk Officer
At Amicus, we demonstrate our integrity by never engaging in bribery or corrupt practices. This is vital to maintaining the trust of our employees, of the patients we serve, and of the customers and partners with whom we work.
Patient Organization Support
Patients and the advocacy organizations that represent them are at the heart of everything we do. It is the mothers, fathers, sons, and daughters – the real people who live with rare disease – who are the focus and beneficiaries of our work. To do that great and meaningful work, we need to understand the true burdens of the individuals, families, and caregivers living with the rare diseases we seek to alleviate, and to grasp the medical needs of those rare disease communities. That understanding informs and energizes everything we do. This is the foundation for our interactions with patient advocacy organizations.
Annually, Amicus publishes a list of its financial support of European Patient Organizations. Although we are not a member of EFPIA, we follow the standards for such reports set out in the EFPIA code.
Amicus has a singular mission: to develop and deliver transformative medicines for people living with rare diseases. In the pursuit of this mission, we collaborate closely with Health Care Professionals (HCPs) and Health Care Organizations (HCOs). Such interactions occur, for example, when we conduct clinical trials, gain critical medical insights regarding how our medicines are, and when we share up-to-date information about our research and products at scientific congresses. In all such interactions, we are committed to providing science-based, truthful, and non-misleading information about our products, and to paying no more than fair market value for needed and legitimate services. Amicus is committed to complying with such transparency laws where required by law and where required by the code of the industry associations of which it is a member.
For purposes of compliance with the requirements of the California Compliance Law (SB 1765) Amicus has established a specific annual aggregate dollar limit of $1,500 on gifts, promotional materials, or items or activities that Amicus may give or otherwise provide to an individual medical or healthcare professional in California on an annual calendar-year basis. This limit includes medical reprints that provide an educational benefit or are related to the healthcare professional’s practice; modest meals associated with a substantive discussion of a Company product or a disease state; and other items or activities permitted under the PhRMA Code and/or the OIG Compliance Guidance. These items and activities are primarily directed to the dissemination or communication of medical and scientific information as a resource for healthcare professionals to assist in making clinical or other medical judgments. This limit may be revised from time to time, in which case the revised limit will be published in this section of the Company websites.
Based on a good faith understanding of the requirements of Section 119402 of the California Health & Safety Code, Amicus Therapeutics Inc. hereby declares that, to the best of its knowledge, its Comprehensive Compliance Program addresses the California statutory requirements for inclusion of policies addressing the OIG Guidance and PhRMA Code and limits on gifts and incentives to health professionals.
At Amicus, we believe that speaking up is crucial to our culture. When something doesn’t seem right, speaking up helps prevent mistakes and misconduct, while also promoting continuous improvement. It is because we care about our employees, patients, customers, and business partners that we take reporting concerns so seriously.
To report a concern, please click on the following link, which will take you to our EthicsPoint hotline site. Your report can be made on a totally confidential and anonymous basis. Amicus investigates all reports and prohibits retaliation against any person who, in good faith, reports known or suspect compliance issues.